A study was done to compare treatment with Filgrastim (r-metHuG-CSF) given at three different times after unrelated bone marrow transplantation (BMT). Sixtynine patients grafted with HLA-A, -B and -DR-compatible unrelated bone marrow were randomized to Filgrastim (5 g/kg/day) starting on day 0 (n = 23), day +5 (n = 23) or day +10 (n = 23) after BMT. No significant differences were detected in hematological recovery, days with fever, days on antibiotics, incidence of bacteremia or need for erythrocyte, platelet and granulocyte transfusions between the three groups. Patients given Filgrastim starting on day 0, day +5 or day +10, respectively, reached an absolute neutrophil count (ANC) Ͼ Ͼ Ͼ0.5 ؋ 10 9 /l on a median of 17, 16 and 16 days after BMT. Starting Filgrastim treatment on day +10, rather than on day 0, reduced the costs of Filgrastim by $1060, with no significant change in the median number of days-tohospital discharge in the three Filgrastim-treated groups. The incidences of acute and chronic GVHD, transplantation-related mortality, relapse, leukemiafree survival and patient survival (PS) were similar in all groups. Keywords: BMT; unrelated donors; G-CSF; engraftment During the past few years, hematopoietic stem cells (HSC) from unrelated donors have been increasingly used for transplantation.
penia, and some studies a reduction in the duration of antibiotic treatment, infections and the length of hospitalization. [13] [14] [15] [16] [17] [18] Experience of G-CSF treatment after unrelated BMT is limited. [19] [20] [21] [22] The present study compares initiation of Filgrastim (r-metHuG-CSF) treatment at 0, +5 or +10 days after HLA-A,-B and -DR-compatible unrelated HSCT.
Patients and methods

Patients
The protocol was approved by the local ethics review committee at Huddinge Hospital, and all patients gave informed consent before the study. Sixty-nine consecutive patients receiving bone marrow from HLA-A, -B and -DR-compatible unrelated donors between April 1994 and September 1997 were studied. The patients were stratified for children Ͻ18 years and adults у18 years, and for patients with or without malignancies. Patients were randomized to receive Filgrastim treatment starting on day 0, day +5 or day +10.
Conditioning and prophylaxis against GVHD
The conditioning regimen and graft-versus-host disease (GVHD) prophylaxis were the same throughout the study period. 23 Sixty-six patients were treated with cyclophosphamide (CY) 60 mg/kg for 2 consecutive days, in combination with total body irradiation (TBI) in a total dose of 10 Gy in a single fraction, and 9 Gy in the pulmonary region at a dose rate of 4 cGy/min. 24 Two patients received busulfan (BU) 4 mg/kg on 4 consecutive days, followed by CY 60 mg/kg for 2 days. 25 One patient with severe aplastic anemia (SAA) received CY and antithymocyte globulin (ATG). All patients were treated with ATG 2 to 5 mg/kg or OKT-3 5 mg/day for 5 days before transplantation. 26 As prophylaxis against GVHD, 64 patients were given cyclosporin A (CsA) 5 mg/kg/day intravenously (i.v.), starting on day Ϫ1. From day +1, CsA 12.5 mg/kg was given orally to maintain blood levels at 200 to 300 ng/ml. Four doses of methotrexate (MTX) were given on day 1 (15 mg/m 2 ), day 3 (10 mg/m 2 ), day 6 (10 mg/m 2 ) and day 11 (10 mg/m 2 ) after transplantation. 27 Five patients with increased bilirubin values received CsA, in combination with prednisolone to avoid MTX toxicity.
Prophylaxis versus infections
All patients were kept in reverse isolation from the start of CY treatment, until neutrophil recovery exceeded 0.5 ϫ 10 9 /l. As gut decontamination, ciprofloxacin, 500 mg twice daily, in combination with oral amphotericin B was used. Co-trimoxazole was given for 6 months after BMT as prophylaxis against Pneumocystis carinii. Acyclovir during the neutropenic phase was given as prophylaxis against HSV to patients with HSV-IgG titers у10 000/l or previously recurrent HSV infection. Until May 1995, blood products from CMV seronegative donors were given only to CMV seronegative patients. Thereafter, leukocytedepleting blood filters have been used.
Donors
All 69 donors were unrelated HLA-A, -B and -DR-compatible. HLA-A and -B class I typing were done serologically before 1996, and after 1996, both serologically and genomically. HLA-DR class II typing was done, using the polymerase chain reaction sequence-specific primers (PCR-SSP) method. 23, 28 Bone marrow was harvested without prior growth factor stimulation and was infused unmanipulated.
Definitions, transfusion policy and IVIG treatment
Neutrophil engraftment was defined as the first day with a sustained absolute neutrophil count (ANC) Ͼ0.5 ϫ 10 9 /l after transplantation. Platelet engraftment was defined as the first day of a platelet count Ͼ30 ϫ 10 9 /l without requiring platelet transfusions. Bacteremia was considered if at least one positive blood culture for bacteria had been obtained in a febrile patient during the first month after transplantation or until discharge. 29 Cytomegalovirus (CMV) disease was defined as CMV infection, verified by biopsy, bronchoalveolar lavage, spinal fluid isolation together with clinical symptoms or typical retinitis. 30 Acute GVHD was graded according to standard criteria 31 and chronic GVHD was assessed in patients alive after day 90. 32 Erythrocyte transfusions were given, when the Hb was Ͻ70 g/l, and platelet transfusions, when the platelet count was Ͻ30 × 10 9 /l. Intravenous immunoglobulin (IVIG) 0.5 g/kg was given to three patients once weekly until day 90, starting in the week before BMT (a total of 13 doses), according to a prospective study protocol 33, 34 (Table 1) .
Study drug and costs
Filgrastim (r-metHuG-CSF), supplied by Roche/Amgen Companies, Stockholm, Sweden, was given in a dose of 5 g/kg. It was administered daily over a period of 30 min by i.v. infusion until the patient's ANC reached Ͼ0.5 ϫ 10 9 /l for 2 consecutive days. The cost of Filgrastim (US $106/300 g) was based on the price charged by the pharmacy.
Statistical analysis
Hematological recovery, the number of days and the dose of Filgrastim were compared, using the non-parametric Advanced: malignant Ͼ1st remission, Ͼ1st chronic phase. CMV+ = positive cytomegalovirus serology before BMT; AML = acute myeloid leukemia; ALL = acute lymphoblastic leukemia; CML = chronic myelogenous leukemia; Other = myelodysplastic syndrome, myeloma, lymphoma, myelofibrosis, severe aplastic anemia and metabolic disorders; Cy/TBI = cyclophosphamide/total body irradiation; Bu/Cy = busulfan/cyclophosphamide; Cy/ATG = cyclophosphamide/antithymocyte globulin; CsA+MTX = cyclosporine A + methotrexate; IVIG = intravenous immunoglobulin.
ANOVA (Kruskal-Wallis) test and the Mann-Whitney U test. Two patients in the Filgrastim-treated groups died before engraftment. They were not included in the engraftment data, using the Mann-Whitney U test, but they were included in the survival analysis. Patients who died within 30 days after HSCT were censored in the analysis of hospitalization. For statistical comparisons of absolute numbers, the chi-square test or Fisher's exact test was used. The probabilities of GVHD, transplantation-related mortality (TRM), relapse and survival rates were compared using the method of Kaplan-Meier with the log-rank test (Mantel-Haenszel). Table 1 shows the baseline characteristics of the patients. The median age of all patients was 23 years (range 1-50); 36 (52%) were males and 33 (48%) were females. Fortythree (62%) of the patients had a positive CMV serology before transplantation. The main diagnoses were acute lymphoblastic leukemia, acute myeloid leukemia and chronic myelogenous leukemia. The characteristics of the patients in the three groups are similar.
Results
Patients
Study drug treatment
The median number of days on Filgrastim treatment, the total dose and toxicity data are given in Table 2 . All patients received a full dose of Filgrastim, as planned, except two who died before engraftment. Five (7%) patients complained of mild to moderate bone pain after administration, but no patient had the dose reduced or discontinued because of toxicity or other complications.
Hematological recovery and transfusions
The median time to reach WBC Ͼ0.2 ϫ 10 9 /l, ANC Ͼ0. /l was similar in the three randomized groups ( Table  2 ). White blood cell recovery (WBC Ͼ0.2 ϫ 10 9 /l) and neutrophil recovery (ANC Ͼ0.5 ϫ 10 9 /l) were reached at a median of 15 and a median of 16 days in the Filgrastimtreated groups (n = 67), respectively. The median time to reach ANC Ͼ0.5 ϫ 10 9 in patients grafted with р2.6 ϫ 10 8 /kg bone marrow cells (median) was 18 (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) days, compared to 15 (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) days in patients grafted with Ͼ2.6 ϫ 10 8 /kg bone marrow cells (P = 0.06). The need for platelets, erythrocytes and granulocytes was similar in the three groups.
Days with fever, on antibiotics and complications
The median number of days with fever Ͼ38.0°C and on parenteral antibiotics were similar in the three groups ( Table 2 ). The occurrence of bacteremia, the incidence of Table 2 Study drug treatment, engraftment, days with fever and on antibiotics, hospitalization, infections and graft-versus-host disease acute GVHD grades II-IV and CMV disease did not differ significantly between the groups. Four patients given Filgrastim, starting on day 0, and nine patients given Filgrastim, starting on day +5, developed chronic GVHD (P = 0.05) ( Table 2) .
Costs and hospitalization
The median costs of Filgrastim treatment were reduced by $1060 when Filgrastim was started on day +10 rather than on day 0. There were no differences in number of days to discharge among the three groups (Table 2) .
Outcome and causes of death
The 1-year transplant-related mortality (TRM), relapse, leukemia-free survival (LFS) and patient survival rates did not differ significantly in the three Filgrastim-treated (Table 3 ). The causes of death are listed in Table 4 .
Discussion
This is the first published randomized study comparing early vs delayed G-CSF treatment after unrelated donor BMT. Sixty-seven (97%) patients had successful engraftment of neutrophils during the study: the two patients who did not, died of infectious complications on days 9 and 10, respectively. No differences in neutrophil or platelet engraftment were seen in the different Filgrastim The median follow-up time was 21 months in the Filgrastim-treated group. treatment groups. Various authors have reported that rHuGM-CSF and rHuG-CSF reduce the number of days with neutropenia after HSCT. 9, [15] [16] [17] However, the optimal day for starting treatment is not known. The objective of this study was to compare initiation of G-CSF on days 0, +5 or +10 after unrelated donor BMT.
Several studies show that a later (6-8 days after BMT) rather than an early start of rHuG-CSF administration gives the same clinical benefits with reduced costs after HSCT. [35] [36] [37] [38] [39] [40] [41] Only one of these studies included recipients of allogeneic HSC. 38 The other studies included only autograft recipients.
In one retrospective study, early (day +1) compared to delayed (day +4) administration of G-CSF after autologous PBPCT resulted in a significant faster (1.5 days) ANC Ͼ0.5 ϫ 10 9 /l recovery, shorter hospitalization (2.3 days) and decrease in days with antibiotics. 42 Our results show that starting G-CSF treatment on day 10 after unrelated BMT did not delay engraftment of neutrophils Ͼ0.5 ϫ 10 9 compared to G-CSF treatment from the day of transplantation.
Also the number of days to reach WBC Ͼ0.2 ϫ 10 9 /l were similar between the three G-CSF-treated groups. This finding may indicate that G-CSF does not have any effect on a small number of neutrophils which may circulate from day 0 to day 10.
The reasons why later initiation of rHuG-CSF treatment may be as effective as early initiation may be that rHuG-CSF acts on relatively mature progenitor cells committed to neutrophilic differentiation 43 and, therefore, the precursor cells need time to mature after HSCT. It has also been shown that the endogenous G-CSF levels are in the same range as those obtained by exogenous administration during the first week after BMT. 44 Therefore, additional G-CSF treatment may have little effect on enhanced engraftment of neutrophils. It has been questioned whether neutrophil engraftment seen in G-CSF post BMT treatment occurs largely in patients transplanted with a low number of progenitor cells. 45 In our study, time to engraftment of ANC Ͼ0.5 ϫ 10 9 /l in patients grafted with more than the median bone marrow cell dose (2.6 ϫ 10 8 /kg recipient weight) showed a trend for faster engraftment (P = 0.06).
Time to engraftment of neutrophils and platelets among the 69 Filgrastim-treated patients was compared to 30 patients who did not receive G-CSF but were given bone marrow from unrelated donors between 1990 and March 1994 at our institution. Twelve patients in the data base of retrospective patients were given Filgrastim during this period; they were not included in the comparison. The historical control patients were treated according to the same protocol as those included in the randomized trial. 26 However, in the historical patients, there were more patients with early disease (defined as 1CR, 1CP or non-hematological malignancies) than in the present study (77% vs 51%; P = 0.03). Furthermore, 83% were given IVIG vs only 4% (P Ͻ 0.001) among the G-CSF-treated patients. However, IVIG treatment was of no benefit in recipients of unrelated marrow and it has therefore been abandoned. 33, 34 In the historical group, 10% received erythropoietin but none in the G-CSF group (P = 0.04).
The median time to reach ANC Ͼ 0.5 × 10 9 /l was 5 days faster in patients treated with G-CSF, 16 (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) days, than in retrospectively untreated patients, 21 (13-28) days (P = 0.004). The median time to platelets Ͼ30 × 10 9 /l was similar; 21 days in both groups. This is in line with other reports about BMT in the allogeneic situation. 21, 22 The Seattle group found that G-CSF or GM-CSF treatment after autologous transplantation delayed the time to platelet independence in patients who received less than 5 × 10 6 CD34 + cells/kg. 46 In our study, time to platelet recovery was similar, 20 (9-100) vs 24 (13-100) days (P = 0.1), if the cell number transplanted was greater than or less than the median number of cells transplanted.
However, the main question is whether an acceleration of neutrophil recovery translates into reduced complications with infections, reduced TRM and reduced cost due to shorter hospitalization. The published experience of G-CSF treatment after unrelated BMT is limited. The reluctance to use G-CSF in the unrelated situation may be due to previous experience published by Schriber and colleagues, 21 who reported an unexpectedly high mortality rate of 45% (five fungemia, three VOD and one VOD/GVHD) within the first 100 days after rHuG-CSF 10 g/kg from day +1 until ANC Ͼ1 ϫ 10 9 /l for 3 consecutive days after unrelated BMT. A study of G-CSF treatment in children showed enhanced neutrophil recovery and comparable day 100 TRM after unrelated BMT compared to historical patients given BMT from HLA-identical siblings. 22 In our study, the 1-year TRM was 35% and the 1-year patient survival rates 59% among all G-CSF-treated patients.
We found an incidence of grades II-IV acute GVHD at 25%. Schriber et al 21 also reported a low incidence of grades II-IV acute GVHD (20%) in patients treated with G-CSF after unrelated BMT.
Pretreatment of donor mice with G-CSF polarizes donor T cell production of type-2 (IL-4 and IL-10) cytokines, which is associated with reduced type-1 cytokine production (IFN-␥ and IL-2) and reduced severity of acute GVHD. 47 A study by Arpinati et al 48 showed that G-CSF mobilizes lymphoid dendritic cells (DC type-2) rather than myeloid dendritic cells (DC type-1) in peripheral blood of normal donors. It has been shown in vitro that DC type-2 induces T cell production of type-2 cytokines. 49 To speculate, this modulation of cytokine production from proinflammatory cytokines to anti-inflammatory cytokines by G-CSF treatment may have contributed to the low incidence of acute GVHD seen in our study. Our use of ATG and HLA class II DNA matched compatible donors may be more important for the low incidence of acute GVHD. 50 We found no differences in the Filgrastim-treated groups with regard to bacteremia, CMV disease, days with fever, use of parenteral antibiotics, GVHD, TRM and outcome. The median number of days on Filgrastim treatment was reduced by 11 days, when treatment was started on day +10 after BMT than when it was started on day 0 (P Ͻ 0.001) and this reduced the cost of Filgrastim by $1060.
Filgrastim was well tolerated, was not discontinued in any patient and we confirm that Filgrastim has a beneficial effect on neutrophil recovery. Filgrastim after unrelated transplantation was safe and initiating treatment on day +10 rather than day 0 or day +5, resulted in lower costs. On the basis of these data, we now give all patients G-CSF, starting on day +10 after allogeneic HSCT.
